H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Newron Pharma (NWPHF) to CHF 43 from CHF 26 and keeps a Buy rating on the shares. The firm says exclusivity for evenamide has been extended via issuance of a new composition-of-matter patent in Europe.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NWPHF:
- EA Pharma Starts Phase III Trial of Newron’s Evenamide for Treatment‑Resistant Schizophrenia in Japan
- Newron Secures EU Patent Extension for Lead Schizophrenia Drug Evenamide
- Newron Wins Long-Term EU Patent Protection for Lead Schizophrenia Drug Evenamide
- Newron Pharma initiated with a Buy at Lucid Capital
- Newron Pharmaceuticals’ Evenamide Advances with ENIGMA-TRS 2 Trial: Analyst Reiterates Buy Rating